Directorio

Es posible que algunos contenidos no estén disponibles en español.
436 clinical trials found.
Brain and Spine Metastasis

We are doing this study to see if the study drug, QTX3034, either with or without cetuximab, is safe and effective for treating KRAS G12D mutated cancer. We are also trying to find the best dose of QTX3034 to use.

Compensation: No
Oncology
Brain and Spine Metastasis

We are doing this study to find out if an investigational drug called QTX3544 (the study drug) is a safe and effective option for KRAS G12V mutated cancer. We want to know how well it works on its own and in combination with a drug called cetuximab, and we are also trying to find the best dose of the study drug to use.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital
Brain and Spine Metastasis

We are doing this study to find out if an investigational drug called RMC-9805 (the study drug) is a safe and effective option for treating KRAS G12D mutated cancer. We are also trying to figure out what dose of the study drug works best for most people.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital
Skin Cancer - Melanoma

We are doing this study to find the most effective, safe dose of a combination of the drugs fianlimab and ceminplimab. We want to know if this combination is an option for people with melanoma. We will compare how well this drug combination works to the usual treatment of relatlimab and nivolumab, which has the brand name Opdualag®.

Compensation: No
Ages: 18-85
Oncology
Duke Raleigh Hospital
Pediatric Cancer

If you choose to join this study, you will:

  • Get 2-6 cycles of Inotuzumab Ozagamicin, lasting 1 month per cycle
  • Get Methotrexate on day one during cycle 1 and on day 28 of cycles 2, 4 and 6
  • Get about 3-5 mL of blood collected prior to treatment and at three time points during cycle 1 and 4 time points during cycle 2

Compensation: No
Oncology
Thoracic Cancer

We are doing this study to find the most effective and safe dose of an experimental drug called LY3537982 (the study drug) for people who have NSCLC that has KRAS G12C mutations.

Compensation: Yes
Ages: 18-100
Oncology
Duke University Hospital, Duke Raleigh Hospital
Research for Children and Teenagers

We are doing this study to find out if an investigational, non-stimulant drug called SPN-812 (the study drug, viloxazine extended-release capsules). The study drug is FDA-approved for children ages 6 and above. It is not approved for children younger than 6, so this study is being done to determine how well it works and how safe it is for preschool-aged children.

Compensation: Yes
Ages: 4-5
Non-Oncology
Duke University Hospital
Skin Cancer - Melanoma

We are doing this study to find out how much skin should be removed from around a melanoma to lower the chances of the melanoma coming back. We don't have enough evidence to know exactly how much skin to remove around the melanoma to give people the best chance at a good outcome.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital